The offering will dilute existing shareholders by ~17-20%, likely pressuring the stock near term. Monitor for potential additional dilution if underwriters exercise the greenshoe option. The increased cash runway supports ongoing clinical programs (RGX-202, ABBV-RGX-314, NAVSUNLI) but does not change the fundamental risk profile.
Drugs in focus
RGNX drug pipeline →surabgene lomparvovec
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.
- Next catalyst
- None dated
What to watchWatch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.
- ◆ NAVSUNLI 6/10 BLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L Named in filing
- ◆ RGX-202 6/10 Phase 3 (pivotal topline complete; BLA submission planned) Named in filing
- ▼ RGX-111 2/10 Phase I/II (on FDA clinical hold since January 2026) Named in filing
- All RGNX drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 17 $9.89entry
- T+1 · 4mo ago +4.35%α +4.51% · $10.32
- T+5 · 4mo ago +3.64%α +4.33% · $10.25
- T+20 · 3mo ago +8.85%α +4.40% · $10.77
- T+60 · 5w ago −21.44%α −26.12% · $7.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
REGENXBIO priced a $100M underwritten public offering of 10M shares at $9.00/share plus 1.1M pre-funded warrants, representing ~17-20% dilution of existing shares. The offering closes July 20, with underwriters holding a 30-day option for an additional 1.67M shares. This capital raise provides cash runway but significantly dilutes current holders.
Key Financial Metrics
Key Facts
- Gross proceeds of ~$100M from 10,003,889 shares at $9.00/share and 1,111,111 pre-funded warrants at $8.9999/warrant
- Underwriters have 30-day option to purchase an additional 1,667,250 shares
- Offering expected to close July 20, 2026
- Joint book-runners: Morgan Stanley, J.P. Morgan, Leerink Partners, Mizuho
- Dilution of ~17-20% based on market cap of $579M at $9.00/share
Financial Impact
$100M gross proceeds with ~17-20% dilution of outstanding shares
Risk Factors
- Further dilution if underwriters exercise the 30-day option for 1.67M additional shares
- Stock price may decline as new shares enter the market and existing holders absorb dilution
- No specific use of proceeds disclosed, raising uncertainty about capital allocation efficiency
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302828273 |
Track record
15 reports on RGNX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 2 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
- Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
- Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
- Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers